Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-26T17:21:37.575Z Has data issue: false hasContentIssue false
  • English
  • Français

Low dose oral iodized oil for control of iodine deficiency in children

Published online by Cambridge University Press:  09 March 2007

Michael Zimmermann ,
Pierre Adou ,
Toni Torresani ,
Christophe Zeder  and
Richard Hurrell
Michael Zimmermann*
Affiliation:
Human Nutrition Laboratory, Swiss Federal Institute of Technology, Zürich, Switzerland
Pierre Adou
Affiliation:
The National Institute of Public Health, Ministry of Health, Abidjan, Côte d'Ivoire
Toni Torresani
Affiliation:
The Department of Pediatrics, University of Zürich, Switzerland
Christophe Zeder
Affiliation:
Human Nutrition Laboratory, Swiss Federal Institute of Technology, Zürich, Switzerland
Richard Hurrell
Affiliation:
Human Nutrition Laboratory, Swiss Federal Institute of Technology, Zürich, Switzerland
*
*Corresponding author: Dr Michael Zimmermann, fax +41 1 704 5710, email [email protected]
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

In areas where iodized salt is not available, oral iodized oil is often used to correct I deficiency despite a lack of consensus on the optimal dose or duration of effect, particularly in children, a main target group. Annual doses ranging from 400 to 1000 mg have been advocated for school-age children. Because lower doses of iodized oil have been shown to be effective in treating I deficiency in adults, the aim of this study was to evaluate the efficacy and safety of a low dose of oral iodized oil in goitrous I-deficient children. Goitrous children (n 104, mean age 8·4 years, range 6–12 years, 47 % female) received 0·4 ml oral iodized poppyseed-oil containing 200 mg I. Baseline measurements included I in spot urines (UI), serum thyroxine (T4), whole blood thyroid-stimulating hormone (TSH), and thyroid-gland volume using ultrasound. At 1, 5, 10, 15, 30 and 50 weeks post-intervention, UI, TSH and T4 were measured. At 10, 15, 30 and 50 weeks, thyroid-gland volume was remeasured. At 30 and 50 weeks the mean percentage change in thyroid volume from baseline was -35 % and -41 % respectively. The goitre rate fell to 38 % at 30 weeks and 17 % at 50 weeks. No child showed signs of I-induced hypo- or hyperthyroidism. UI remained significantly increased above baseline for the entire year (P < 0·001); the median UI at 50 weeks was 97 μg/l, at the World Health Organization cut-off value (100 μg/l) for I-deficiency disorders risk. In this group of goitrous children, an oral dose of 200 mg I as Lipiodol (Guerbert, Roissy CdG Cedex, France) was safe and effective for treating goitre and maintaining normal I status for at least 1 year.

Keywords

IodineGoitre
Type
short communication
Information
British Journal of Nutrition , Volume 84 , Issue 2 , August 2000 , pp. 139 - 141
Copyright
Copyright © The Nutrition Society 2000

References

Bailey, KV & Clugston, GA (1990) Iodine deficiency disorders. In The Global Burden of Disease and Risk Factors in 1990 ]Murray, CJL and Lopez, AD, editors]. Geneva: World Health Organization.Google Scholar
Bautista, A, Barker, PA, Dunn, JT, Sanchez, M and Kaiser, DL (1982) The effects of oral iodized oil on intelligence, thyroid status, and somatic growth in school-age children from an area of endemic goiter. American Journal of Clinical Nutrition 35, 127–134.CrossRefGoogle ScholarPubMed
Benmiloud, M, Lamine, Chaouki M, Gutekunst, R, Teichert, HM, Graham, Wood W and Dunn, JT (1994) Oral iodized oil for correcting iodine deficiency: optimal dosing and outcome indicator selection. Journal of Clinical Endocrinology and Metabolism 79, 20–24.Google ScholarPubMed
Bourdoux, P, Delange, F, Gerard, M and Mafuta, M (1978) Evidence that cassava ingestion increases thiocyanate formation: a possible etiologic factor in endemic goiter. Journal of Clinical Endocrinology and Metabolism 46, 613–621.CrossRefGoogle ScholarPubMed
DeLange, F (1998) Risks and benefits of iodine supplementation. Lancet 351, 923–924.CrossRefGoogle ScholarPubMed
Eltom, M, Karlsson, FA, Kamal, AM, Boström, B and Dahlberg, PA (1985) Oral iodized oil in the treatment and prophylaxis of endemic goiter. Journal of Clinical Endocrinology and Metabolism 61, 1112–1117.CrossRefGoogle ScholarPubMed
Furnée, CA, Pfann, GA, West, CE, van der Haar, F, van der Heide, D and Hautvast, JGAJ (1995) New model for describing urinary iodine excretion: its use for comparing different oral preparations of iodized oil. American Journal of Clinical Nutrition 61, 1257–1262.CrossRefGoogle ScholarPubMed
Latapie, JL, Clerc, M and Beda, B (1981) Biological and clinical aspects of endemic goiter in the Man region of Côte d'Ivoire. Annals Endocrinologie 42, 517–530.Google Scholar
Lipiodol Scientifique, International Division (1998) Recommended Annual Dosages for the Treatment of Iodine Deficiency and Associated Diseases. Roissy CdG Cedex: Guerbet.Google Scholar
Pino, S, Fang, SL and Braverman, LE (1996) Ammonium persulfate: a safe alternative oxidizing reagent for measuring urinary iodine. Clinical Chemistry 42, 239–243.CrossRefGoogle ScholarPubMed
Stanbury, JB, Ermans, AE, Bourdoux, P, Todd, C, Oken, E, Tonglet, R, Vidor, G, Braverman, LE and Medeiros-Neto, G (1998) Iodine induced hyperthyroidism: occurrence and epidemiology. Thyroid 8, 83–100.CrossRefGoogle ScholarPubMed
Tonglet, R, Bourdoux, P, Minga, T and Ermans, AM (1992) Efficacy of low oral doses of iodized oil in the control of iodine deficiency in Zaire. New England Journal of Medicine 326, 236–241.CrossRefGoogle ScholarPubMed
Torresani, T and Scherz, R (1986) Thyroid screening of neonates without use of radioactivity: evaluation of time-resolved fluoroimmunoassay of thyrotropin. Clinical Chemistry 32, 1013–1016.CrossRefGoogle ScholarPubMed
World Health Organization/International Committee on Control of Iodine Deficiency Disorders (1997) Recommended normative values for thyroid volume in children aged 6–15 years. Bulletin of the World Health Organization 75, 95–97.Google Scholar
World Health Organization, United Nations International Childrens' Emergency Fund and International Committee on Control of Iodine Deficiency Disorders (1994) Indicators for Assessing Iodine Deficiency Disorders and their Control through Salt Iodinization, WHO/NUT 94.6. Geneva: WHO.Google Scholar
Zimmermann, MB, Adou, P, Torresani, T, Zeder, C and Hurrell, RF (2000) Persistence of goiter despite oral iodine supplementation in goitrous children with iron-deficiency anemia in Côte d'Ivoire. American Journal of Clinical Nutrition 71, 88–93.CrossRefGoogle ScholarPubMed